Apolipoprotein A-I therapy promise, challenges, and disappointment.
Michael H
MH
Davidson
D016632:Apolipoprotein A-I / Q000096:biosynthesis / Q000097:blood* / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood* / Q000187:drug effects; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D052999:Quinazolinones; D016896:Treatment Outcome
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011799:Quinazolines; D052999:Quinazolinones; C000628794:apabetalone